New drug targets Hard-to-Treat tumors in early trial
Disease control
Completed
This early-phase study tested a new drug called SAIL66 in 22 adults with advanced solid tumors that have a specific protein (CLDN6). The main goals were to check safety, find the right dose, and see if the drug can shrink tumors. Participants received the drug by infusion, and re…
Phase: PHASE1 • Sponsor: Chugai Pharmaceutical • Aim: Disease control
Last updated May 13, 2026 16:03 UTC